Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 17/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | SNCA | P37840 | 1/20 | 0.67 |
| ▸ | SULT1A1 | P50225 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | GLA | P06280 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.51 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1638231 | 0.85 | APP (0.74) | APPMAPTSNCAMEN1GLA | |
| SCHEMBL24332359 | 0.84 | APP (0.78) | APPMAPTSNCASULT1A1MEN1 | |
| SCHEMBL13816575 | 0.82 | APP (0.74) | APPMAPTSULT1A1MEN1GLA | |
| SCHEMBL28868335 | 0.81 | APP (0.74) | APPMAPTMEN1GLAGAA | |
| SCHEMBL24038224 | 0.81 | APP (0.72) | APPMAPTSULT1A1GLAGAA | |
| SCHEMBL24332463 | 0.80 | APP (0.72) | APPMAPTSULT1A1MEN1GLA | |
| SCHEMBL2628262 | 0.80 | APP (1.00) | APPMAPTSNCASULT1A1MEN1 | |
| SCHEMBL178156 | 0.80 | APP (1.00) | APPMAPTSNCASULT1A1MEN1 | |
| SCHEMBL12207349 | 0.79 | APP (1.00) | APPMAPTSNCASULT1A1MEN1 | |
| SCHEMBL21043888 | 0.79 | APP (0.72) | APPMAPTSNCASULT1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080305040-A1 | In Vivo or in Vitro Method For Detecting Amyloid Deposits Having at Least One Amyloidogenic Protein | UNIVERSITY OF PITTSBURGH | 2008-12-11 | — | — | US | disclosed |
| EP-1937260-A2 | IN-VIVO AND IN-VITRO METHOD FOR DETECTING AMYLOID DEPOSITS HAVING AT LEAST ONE AMYLOIDOGENIC PROTEIN | University of Pittsburgh (US) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007035405-A2 | IN-VIVO AND IN-VITRO METHOD FOR DETECTING AMYLOID DEPOSITS HAVING AT LEAST ONE AMYLOIDOGENIC PROTEIN | UNIVERSITY OF PITTSBURGH (US) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080305040-A1 | In Vivo or in Vitro Method For Detecting Amyloid Deposits Having at Least One Amyloidogenic Protein | TTR, APBA1, APP | APP 3/4885MAPT 214/4885SNCA 1471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.